Akari Matsuoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akari Matsuoka has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ayumi Gomyo
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications - Hideki Nakasone
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications Kaisuke Yamamoto
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publicationsKazuki Yoshimura
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publicationsKoki Hashino
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications- Kosuke Takano
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications
Latest Publications
- 15 October 2026
- Published by Wiley in British Journal of Haematology
Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation
Summary: Th17, a subset of helper T cells that produce interleukin‐17 (IL‐17), is thought to play a pivotal role in the pathogenesis of chronic graft‐versus‐host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo‐HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo‐HSCT were available. Th17 was detected and sorted by flow cytometry, and T‐cell receptor (TCR) repertoire was analysed by a next‐generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17‐TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo‐HSCT, which might be associated with the development of chronic GVHD.
- 15 October 2026
- Published by Wiley in British Journal of Haematology
Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation
Summary: Th17, a subset of helper T cells that produce interleukin‐17 (IL‐17), is thought to play a pivotal role in the pathogenesis of chronic graft‐versus‐host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo‐HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo‐HSCT were available. Th17 was detected and sorted by flow cytometry, and T‐cell receptor (TCR) repertoire was analysed by a next‐generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17‐TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo‐HSCT, which might be associated with the development of chronic GVHD.
- 12 October 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70337
A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation
Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.
- 12 October 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70337
A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation
Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.
- 6 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1762-1772
Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft‐versus‐host disease
Summary: Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft‐versus‐host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo‐HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo‐HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high‐TXN group showed a lower cumulative incidence of grade II–IV acute GVHD (100‐day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance ( p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high‐TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone ( p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.
- 6 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1762-1772
Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft‐versus‐host disease
Summary: Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft‐versus‐host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo‐HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo‐HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high‐TXN group showed a lower cumulative incidence of grade II–IV acute GVHD (100‐day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance ( p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high‐TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone ( p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.